# An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer

> **NCT02784158** · — · NO_LONGER_AVAILABLE · sponsor: **Ariad Pharmaceuticals**

## Conditions studied

- Non-small Cell Lung Cancer
- Lung Cancer
- Advanced Malignancies
- Carcinoma

## Interventions

- **DRUG:** Brigatinib

## Key facts

- **NCT ID:** NCT02784158
- **Lead sponsor:** Ariad Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2018-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02784158

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02784158, "An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02784158. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*